Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.
- Daniel M. Halperin
- , Michael Morris
- , Gary A. Ulaner
- , Jonathan R. Strosberg
- , Samuel H. Mehr
- , Daneng Li
- , Heloisa P. Soares
- , Lowell Brian Anthony
- , Sandy Diana Kotiah
- , Heather Jacene
- , Margot ET Tesselaar
- , Pamela L. Kunz
- , Denis Vasconcelos Ferreira
- , Joanne Li
- , Kimberly Ma
- , Jessica Rearden
- , Susan Moran
- , Thomas A. Hope
- , Simron Singh
Producción científica: Review article › revisión exhaustiva
7
Citas
(Scopus)